Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 6/20 | 0.51 |
| ▸ | PRKACA | P17612 | 2/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.44 |
| ▸ | HINT1 | P49773 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919327 | 0.92 | PRKACA (0.48) | P2RY2PRKACAP2RY6P2RY4HINT1 | |
| SCHEMBL7919322 | 0.87 | LMNA (0.53) | P2RY2PRKACA | |
| SCHEMBL26320825 | 0.85 | P2RY2 (0.57) | P2RY2PRKACAP2RY6P2RY4HINT1 | |
| SCHEMBL20668749 | 0.85 | P2RY2 (0.57) | P2RY2PRKACAP2RY6P2RY4HINT1 | |
| SCHEMBL22387135 | 0.85 | P2RY2 (0.57) | P2RY2PRKACAP2RY6P2RY4HINT1 | |
| SCHEMBL23066250 | 0.85 | P2RY2 (0.57) | P2RY2PRKACAP2RY6P2RY4HINT1 | |
| SCHEMBL12102288 | 0.81 | P2RY6 (0.47) | P2RY2P2RY6P2RY4P2RY14NT5E | |
| SCHEMBL12102270 | 0.81 | P2RY6 (0.47) | P2RY2P2RY6P2RY4P2RY14NT5E | |
| SCHEMBL7913039 | 0.80 | P2RY2 (0.45) | P2RY2P2RY6P2RY4P2RY14NT5E | |
| SCHEMBL7905695 | 0.77 | LMNA (0.57) | P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | HDAC5, HDAC7, HDAC4 | P2RY2 4327/4885PRKACA 2180/4885P2RY6 4297/4885 |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | CD74, HLA-DRB1, HDAC5 | P2RY2 4607/4885PRKACA 2146/4885P2RY6 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.